Press coverage about Dova Pharmaceuticals (NASDAQ:DOVA) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dova Pharmaceuticals earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 48.4618535373206 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Several brokerages have recently commented on DOVA. Leerink Swann upgraded Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price objective on the stock in a research report on Tuesday. J P Morgan Chase & Co began coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They set an “overweight” rating and a $35.00 price objective on the stock. Finally, Jefferies Group LLC began coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They set a “buy” rating and a $30.00 price objective on the stock.

Dova Pharmaceuticals (NASDAQ:DOVA) traded down 0.82% during trading on Friday, reaching $24.28. The company had a trading volume of 108,929 shares. Dova Pharmaceuticals has a one year low of $18.18 and a one year high of $28.24. The company’s market capitalization is $622.83 million. The firm’s 50 day moving average is $24.98 and its 200 day moving average is $24.27.

Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.08). On average, equities research analysts predict that Dova Pharmaceuticals will post ($1.40) earnings per share for the current year.

In other news, VP Kevin Laliberte acquired 6,200 shares of the company’s stock in a transaction that occurred on Wednesday, July 5th. The shares were bought at an average price of $17.00 per share, with a total value of $105,400.00. Following the completion of the purchase, the vice president now directly owns 6,200 shares in the company, valued at $105,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Alex Sapir acquired 20,100 shares of the company’s stock in a transaction that occurred on Wednesday, July 5th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $341,700.00. Following the purchase, the chief executive officer now owns 20,100 shares of the company’s stock, valued at $341,700. The disclosure for this purchase can be found here. In the last three months, insiders purchased 147,839 shares of company stock worth $2,823,538.

ILLEGAL ACTIVITY NOTICE: “Dova Pharmaceuticals (DOVA) Receives Media Impact Score of 0.23” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Insider Buying and Selling by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.